Please check your internet connection and try again.
# L-Ornithine L-Aspartate (LOLA)
## Overview
L-ornithine L-aspartate (LOLA) is a stable salt of two amino acids that serves as a substrate for the urea cycle and glutamine synthesis. It is primarily used to lower ammonia levels in patients with liver disease.
## Primary Indications
* Treatment of hyperammonemia in patients with chronic liver disease (e.g., cirrhosis, hepatitis).
* Adjunctive therapy for latent or manifest hepatic encephalopathy (HE).
## Adult Dosing
* **Oral (Granules):** 3 g to 6 g (1–2 sachets) three times daily, taken with or after meals dissolved in liquid.
* **Intravenous (Severe HE):** Up to 20 g per 24 hours. In severe cases, 40 g may be administered via continuous infusion, provided the infusion rate does not exceed 5 g/hour.
## Pediatric Dosing
* **Establishment:** Safety and efficacy in children are not well-established. Use is generally discouraged unless directed by a pediatric hepatologist under specialized protocols. If used, dosing is typically weight-based and highly variable by local institutional guidelines.
## Dose Adjustments
* **Renal Impairment:** Reduce dose in patients with severe renal impairment (creatinine > 3 mg/dL) due to potential accumulation. No standardized guidelines exist for adjustment; monitor blood urea nitrogen (BUN) and creatinine closely.
## Contraindications
* Hypersensitivity to the active ingredients.
* Severe renal insufficiency (renal failure).
## Adverse Effects
* **Common:** Nausea, vomiting, stomach pain, flatulence, diarrhea.
* **Less Common:** Arthralgia, limb pain.
* **Rare:** Allergic skin reactions, excessive sweating.
## Key Drug Interactions
* **General:** No clinically significant drug-drug interactions have been widely documented. However, caution is advised when combined with other agents that affect nitrogen metabolism or CNS function.
## Monitoring
* **Parameters:** Monitor serum ammonia levels (if available), BUN, serum creatinine, and clinical assessment of mental status (reversal of encephalopathy).
* **Safety:** Monitor for signs of infusion site reactions if given intravenously.
## Clinical Pearls
* LOLA acts by providing substrates for the urea cycle (ornithine) and for glutamine synthesis (aspartate), effectively "trapping" ammonia even when the urea cycle is impaired.
* LOLA is not a replacement for traditional first-line therapies for HE, such as lactulose or rifaximin, but is used as an adjunct.
* Advise patients to dissolve granules in substantial amounts of fluid (e.g., a glass of water/tea) to ensure proper ingestion.
* Rapid IV administration may cause nausea or vomiting; maintain infusion rates strictly under 5 g/hour.
***
*Disclaimer: This information is for educational purposes. Clinical practice varies by country and institution. Always verify specific dosing, safety, and contraindications by consulting the official product monograph or current hospital-approved clinical pharmacy guidelines before prescribing or administering medication.*
